Leqvio (Inclisiran)

Inclisiran is a small interfering RNA that specifically binds to the messenger RNA that codes for PCSK9 in liver cells. By degrading this mRNA, it reduces PCSK9 protein production, allowing more LDL receptors to recycle to the cell surface and clear LDL‑C from the blood.

The prescribed dose of Leqvio is determined by the treating physician. Typically, a single 284 mg subcutaneous injection is administered, followed by a second dose three months later and then every six months thereafter, but exact scheduling is individualized.

Safety of Leqvio during pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and decisions should be made by a qualified healthcare professional.

To order Leqvio, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Leqvio uses siRNA technology to silence PCSK9 production, offering dosing only twice yearly after the initial loading period, whereas monoclonal antibody PCSK9 inhibitors require injections every two to four weeks. Both classes lower LDL‑C, but Leqvio’s infrequent dosing may improve adherence for some patients.

Leqvio must be stored refrigerated between 2 °C and 8 °C. Keep the prefilled syringe in its original packaging, protect it from light, and do not freeze or shake the product. If temporary temperature excursions occur, consult the product label before use.

Leqvio is given as a subcutaneous injection using the prefilled syringe provided. The injection is typically performed by a healthcare professional in a clinical setting. The recommended injection sites are the abdomen or thigh, rotating sites with each administration.

Serious adverse events associated with Leqvio include severe allergic reactions such as anaphylaxis, significant injection‑site necrosis, and marked elevations in liver enzymes. Patients should be monitored for signs of hypersensitivity, persistent injection‑site problems, or abnormal liver function tests.

Leqvio should not be used in individuals with known hypersensitivity to inclisiran or any component of the formulation. It is also contraindicated in pregnant or breastfeeding women until safety is established, and caution is advised in patients with severe hepatic impairment.